IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Confirmation No: 4470

SCHIEMANN et al.

Group Art Unit: 1625

Application Serial No.: 10/583,689 Examiner: Seaman, D Margaret M

Filed: June 20, 2006

Attorney Docket No.: 978725.10/MPG-P009.1

For: 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE

DERIVATIVES

REQUEST TO CORRECT THE INVENTORSHIP IN THE PATENT APPLICATION UNDER 37 CFR § 1.48(a)(1)

Mail Stop Amendment Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450 February 13, 2007

Sir:

Pursuant to 37 CFR §1.48 (a), the applicants hereby submit the following documents in order to correct the inventorship for the above named patent application.

- 1. Request to correct the inventorship (this document).
- 2. A statement from each person being deleted as an inventor that the error in inventorship occurred without deceptive intention on his or her part.
 - 3. A declaration by the actual inventors as required by 37 CFR § 1.63.
 - 4. The processing fee set forth in 37 CFR § 1.17(i).
- 5. The written consent of the assignee required under 37 CFR §1.48 (a)(5). Attached statement under 37 CFR § 3.73(b).

Applicants respectfully request correction of inventorship.

Respectfully submitted,

Ronald J. Kamis

Registration No.: 41,104

Customer No.: 49442 Baker & Daniels LLP

805 15th Street, NW, Suite 700 Washington, DC 20005 Telephone No.: (202) 312-7440

Facsimile No.: (202) 312-7460

RJK/maj

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

SCHIEMANN, Kai et a.	Group: 1625
Serial No. 10/583,689) Conf. No.: 4470
Filed: June 20, 2006	Examiner: Seaman, D Margaret M

Title: 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

T...... 1:--4:--- - C

STATEMENT FROM PERSON BEING DELETED AS AN INVENTOR THAT THE ERROR IN THE INVENTORSHIP OCCURRED WITHOUT DECEPTIVE INTENTION ACCORDING TO 37 C.F.R. § 1.48 (a)(2)

Dear Sir:

I, a person who is being deleted as an inventor by a request submitted to correct the inventorship of this patent application do hereby state that the inventorship error occurred without deceptive intention on my part.

Soheila Fuzali
Soheila ANZALI

Dated: 31th January, 2008

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re application of)	
SCHIEMANN, Kai et a.) Group: 1625	
Serial No. 10/583,689) Conf. No.: 4470	
Filed: June 20, 2006) Examiner: Seaman, D Margaret M	
Title: 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES		
Commissioner for Patents	•	
P.O. Box 1450		
Alexandria, VA 22313-1450		
	EING DELETED AS AN INVENTOR THAT THE	
ERROR IN THE INVENTORSHIP O	CCURRED WITHOUT DECEPTIVE INTENTION	
ACCORDING TO 37 C.F.R. § 1.48 (a)(2)		
	•	
D 0.		

Dear Sir:

I, a person who is being deleted as an inventor by a request submitted to correct the inventorship of this patent application do hereby state that the inventorship error occurred without deceptive intention on my part.

Hulga Drosdat

Helga DROSDAT

Dated: 0 5. Feb. 2008 , 2008

IN THE UNITED STATE PATENT AND TRADEMARK OFFICE

In re application of SCHIEMANN, Kai et a.) Group: 1625	
Serial No. 10/583,689) Conf. No.: 4470	
Filed: June 20, 2006	Examiner: Seaman, D Margaret M	
Title: 2-(HETERO)ARYL-SUBSTITUTED	TETRAHYDROQUINOLINE DERIVATIVES	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 STATEMENT FROM PERSON BEING DELETED AS AN INVENTOR THAT THE ERROR IN THE INVENTORSHIP OCCURRED WITHOUT DECEPTIVE INTENTION ACCORDING TO 37 C.F.R. § 1.48 (a)(2)		
Dear Sir:		
	s an inventor by a request submitted to correct the	
inventorship of this patent application do he	reby state that the inventorship error occurred without	
deceptive intention on my part.	7	

Bjoern HOCK

n 5 Feb. 2008

n 5 Feb. 2008

additional form(s) attached hereto

Date: Citizen of: DE

Date: Citizen of: DE

As the below named inventor(s), I/we declare that:

This declaration is directed to:

FULL NAME OF INVENTOR(S)

Inventor one: SCHIEMANN Kai

Inventor two: EMDE, Ulrich

Additional inventors or a legal representative are being named on

Signature:

Signature:

Title of Invention

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES

☐ The attached application, or	
✓ Application No. 10/583,689 filed on June 20, 2006	
As amended on(if applicable);	
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;	
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. WARNING:	
Petitoner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify that. Personal information such as social security numbers, bank account numbers contributed to the contribute of the contributed of the contributed to the contributed to the USPT to apply the USPT to appl	
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Pacerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES

Invention		
As the belo	named inventor(s), I/we declare that:	
This declar	ion is directed to:	
	The attached application, or	
	Application No. 10/583.689 filed on June 20, 2006	
	As amended on (if applicable);	
I/we believe	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a paten	is

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above:

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)	0 5, Feb. 2008
Inventor one: FINSINGER Dirk	Date:
Signature: Diff fory	Citizen of: _DE
Inventor two: _GLEITZ Johannes	Date: 0.5, Feb. 2008
Signature: John es than	Citizen of: _DE
Additional inventors or a legal representative are being named on	additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

Title of Invention

publicly available.

Approved for use through 06/30/2010, OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) of 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES

ı			
-As the below named inventor(s), I/we declare that:			
ı	This declaration is directed to:		
ı	☐ The attached application, or		
	✓ Application No10/583,689 filed on June 20, 2006		
	As amended on (if applicable);		
	I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;		
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;			
	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT International filling date of the continuation-in-part application.		
ı	WARNING:		
	Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify theft. Personal information such as social security numbers, bank account numbers credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO. Petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (numbers an on-publication eth) at 7 CFR 1.213(a) is made in the application).		

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like a punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not

FULL NAME OF INVENTOR(S)	N E Ech
Inventor one: REUBOLD Helmut	0 5, Feb. 2008
Signature: Mullist Gululd	Citizen of: _DE
Inventor two: ZENKE Frank	Date: 05 Fep. 2008
Signature:	Citizen of: _DE
Additional inventors or a legal representative are being named on	additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CPR 1.83. The information is required to obtain or retain a benefit by the public which is to find up the UBPTO to process) an application. Confidentiality is governed by 35 U.S.C. 22 and 37 CPR 1.11 and 11.4. This collection is estimated to take 1 minute to compiler, including spathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual conseq. Any comments on the amount of them pays unrequise to complete this form and/or supplements on the amount of them pays unrequise to complete this form and/or supplements of the s

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Merck Patent GmbH		
Application No./Patent No.: 10/583,689 Filed/Issue Date: 20th June, 2006		
Entitled: 2-(HETERO)ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES		
Merck Patent GmbH , a Corporation		
(Name of Assignee) (Type of Assignee, e.g., corporation	on, partnership, university, government agency, etc.)	
states that it is: 1. $\boxed{\mathbf{x}}$ the assignee of the entire right, title, and interest; or		
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)	(¥)	
in the patent application/patent identified above by virtue of either:		
A. X An assignment from the inventor(s) of the patent application/patent identified in the United States Patent and Trademark Office at Reel 018020, Frail thereof is attached.		
B. A chain of title from the inventor(s), of the patent application/patent identified	above, to the current assignee as follows:	
From: To: The document was recorded in the United States Patent and Tradema	rk Office at	
Reel, Frame, or for which a copy		
O Francis		
The document was recorded in the United States Patent and Tradema	rk Office at	
Reel, Frame, or for which a co	py thereof is attached.	
3. From:To:		
The document was recorded in the United States Patent and Tradema Reel, or for which a co		
Additional documents in the chain of title are listed on a supplemental sher		
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
	13 FEB. 2008	
Signature	Date	
Ronald J. Kamis REG NO. 41,104	(202) 312-7029	
Printed or Typed Name	Telephone Number	
Attorney for Applicant		
Title		

This collection of information is required by 37 CFR 373(s). The information is required to obtain or retain a benefit by the public which is to file (and by the opposite of process) as application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1-11 and 14.1. This collection is estimated to task 21 minutes to complete, including pathenting, preparing, and submitting the completed application from to the USPTO. Then will very depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for receiving this buston, should be sent to the Chief Information Officer, U.S. Patent and Trademack Office, U.S. Department of Commence, P.O. Box 14(s), Alexandia, V.A. 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.